As obesity and metabolic disease reshape pharmaceutical pipelines, Reliant Life Sciences Vice President Ben Locwin sees the next opportunity moving beyond weight loss alone toward new mechanisms, better outcomes, and the capabilities required to bring them to market.
GLP-1 therapies have fundamentally changed the conversation around obesity and metabolic disease.
The scale of the opportunity is difficult to ignore. According to the CDC’s latest national estimates, 40.3% of U.S. adults have obesity, while another 31.7% are overweight.
At the same time, the therapeutic opportunity is expanding beyond weight management. Obesity intersects with type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea, metabolic dysfunction-associated steatohepatitis (MASH), and other conditions that are increasingly being addressed as part of a broader metabolic disease landscape.
For Ben Locwin, PhD, MBA, Vice President at Reliant Life Sciences, the success of today’s GLP-1 therapies is only part of the story. Locwin has discussed metabolics as one of the industry’s fastest-growing therapeutic categories, but as investment and innovation accelerate, he believes pharmaceutical leaders should be asking a more specific question: Where can our organization create differentiated value in the evolving metabolic disease ecosystem?
At Reliant Life Sciences, Locwin works with pharmaceutical and biotech organizations navigating the quality, regulatory, manufacturing, and operational challenges that emerge as therapies advance from development toward commercialization.
The GLP-1 Market Is Becoming a Metabolic Disease Market
GLP-1 medicines are already moving well beyond their original role in diabetes and obesity.
A 2026 review in Nature Medicine describes their expanding use across obesity-related comorbidities including cardiovascular disease, peripheral artery disease, and obstructive sleep apnea.
That expansion is also visible in regulatory approvals. In 2025, the FDA approved semaglutide for adults with noncirrhotic MASHwith moderate-to-advanced liver fibrosis, illustrating how therapies associated with obesity and diabetes are moving into adjacent metabolic indications.
For drug developers, the competitive landscape is expanding with it.
Drug developers are now exploring different mechanisms, indications, delivery models and combinations that could address a much broader spectrum of metabolic disease.
“The strategic question isn’t whether you need to develop your own GLP-1… It’s where your organization can create differentiated value in the metabolic disease ecosystem.”
Ben Locwin, PhD, MBA
Vice President, Reliant Life Sciences
Three Signals Shaping the Next Metabolic Pipeline
Recent pipeline activity offers clues about where the next opportunities in metabolic disease may emerge.
1. Multi-Pathway Therapies Are Expanding the Target
One of the clearest trends is the move beyond targeting GLP-1 alone.
A May 2026 review in Nature Reviews Drug Discovery describes an expanding pipeline of multi-receptor agonists targeting combinations of GLP-1, GIP, glucagon, and amylin. Programs such as zenagamtide and retatrutide illustrate how quickly the field is moving beyond a single pathway.
Locwin sees the bigger story in what comes next. If complementary pathways can produce different outcomes for different patient needs, the market may eventually segment around metabolic profile, comorbidities, body composition, tolerability and treatment goals.
For drug developers, that creates opportunities to think beyond competing directly with today’s leading therapies and instead identify where a different mechanism or combination could address a specific unmet need.
2. Oral Small Molecules Could Change the Manufacturing Equation
Innovation isn’t limited to biological targets. Drug modality and delivery are changing, too.
The FDA’s 2026 approval of orforglipron marked the first approval of a small-molecule GLP-1 receptor agonist for obesity, providing an oral alternative to peptide-based obesity drugs. The pipeline continues to develop, with a June 2026 Phase 2b study published in Nature Medicine reporting placebo-adjusted body-weight reductions of up to 11.3% at 36 weeks for the oral small-molecule GLP-1 candidate aleniglipron.
For pharmaceutical organizations, the implications reach directly into development and manufacturing strategy.
Peptides and chemically synthesized small molecules introduce different considerations around process development, manufacturing, validation, stability, supply and scale. As metabolic therapies reach increasingly large patient populations, manufacturability may become a competitive consideration alongside clinical differentiation.
3. The Next Metric May Be the Quality of Weight Loss
Perhaps the most interesting next frontier, according to Locwin, is not simply how much weight patients lose. It’s what kind of weight they lose.
Significant weight reduction can include both fat and lean tissue. As increasingly effective obesity treatments produce greater total weight loss, researchers are paying closer attention to body composition and how lean mass might be better preserved.
Locwin has been watching another area for several years: myostatin inhibition.
Myostatin helps regulate skeletal muscle growth, making the pathway a potential target for preserving lean tissue during weight loss. As obesity therapies drive greater total weight loss, Locwin expects the conversation to shift from pounds lost toward body composition and longer-term metabolic health.
The science is still developing, and important questions around function, safety and long-term outcomes remain. But the direction is worth watching. The next competitive benchmark may not be weight loss alone. It may be the quality of that weight loss.
“Weight loss alone won’t tell the whole story. Body composition, lean tissue preservation, and long-term metabolic health could become increasingly important measures of success.”
Ben Locwin, PhD, MBA
Vice President, Reliant Life Sciences
Scientific Opportunity Is Only Half the Equation
For pharmaceutical and biotech companies, a promising mechanism still has to survive the realities of development, scale-up and commercialization.
That can introduce challenges across CMC, regulatory strategy, process development, technology transfer, commissioning and qualification, validation, quality systems and commercial manufacturing. And those requirements can look very different depending on the program.
A peptide, an oral small molecule, a multi-receptor therapy and a biologic designed to preserve muscle mass can each introduce different development and manufacturing considerations.
For companies evaluating opportunities in metabolic disease, pipeline strategy therefore needs to be accompanied by an equally rigorous execution strategy. That means asking:
- Can our manufacturing infrastructure support the modality and scale?
- Where could capacity, supply or technology transfer constraints emerge?
- What quality, validation and regulatory requirements need to be anticipated now?
- Do we have the MSAT, manufacturing and specialized expertise required as the program advances?
These questions become increasingly important as a promising therapy moves closer to the clinic and commercialization. Gaps in expertise, capacity or planning that seem manageable early in development can become much harder to solve as timelines accelerate and regulatory requirements increase.
This is where Reliant Life Sciences supports biotech and pharmaceutical organizations. RLS provides experienced specialists across Quality, Validation, Regulatory, Manufacturing Science & Technology (MSAT) and technology transfer who can step into complex programs at critical stages, helping internal teams solve execution challenges while meeting the quality and compliance requirements that regulated development demands.
From Pipeline Promise to Regulated Execution
Emerging metabolic programs may require expertise across:
- CMC & Tech Transfer
- CQV & Validation
- Quality Systems
- Regulatory Strategy
- MSAT
- Manufacturing & Scale-Up
The Opportunity Is Bigger Than GLP-1
For pharmaceutical executives, asking “How do we participate in GLP-1s?” may already be too narrow.
A better question is: Where can our science, development capabilities and manufacturing expertise create differentiated value across the metabolic disease ecosystem?
Locwin believes the companies best positioned for the next phase won’t necessarily be those trying to replicate today’s winners. They’ll be the ones that identify the next unmet need, understand what it takes to develop and manufacture a solution, and build the capabilities required to execute.
As metabolic pipelines become more diverse, that execution will require expertise spanning regulated development, quality, validation, regulatory strategy, technology transfer and manufacturing.
Reliant Life Sciences helps biotech and pharmaceutical organizations bring that expertise to the moments where execution matters most. Talk with a Reliant Life Sciences Expert.
Written by: Ben Locwin, Vice President at Reliant Life Sciences.
